For Quick Alerts
For Daily Alerts

Sun Pharma Shares Up 4% On FDA Approval


Sun Pharma saw its shares rally 4% in a falling market, after one of the company's subsidiaries received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Gleevec.

Imatinib Mesylate tablets 100mg and 400mg are the terapeutic equivalents of Novartis' Gleevec tablets.

Sun Pharma Shares Up 4% On FDA Approval
As per IMS MAT August 2015, these tablets have annual sales of approximately US$ 2.5 billion in the US.

These tablets are indicated for the treatment of chronic myeloid leukemia. The Sun Pharma subsidiary, being the first-to-file an ANDA for generic Gleevec with a para IV certification, is eligible for 180-days marketing exclusivity in the US. Under the terms of a settlement agreement with Novartis, the Sun Pharma subsidiary is permitted to launch its version of generic Gleevec.

Read more about: sun pharma
Story first published: Friday, December 4, 2015, 11:29 [IST]
Company Search
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Goodreturns sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Goodreturns website. However, you can change your cookie settings at any time. Learn more